King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. AlFadel AlShaibani
Dr. AlFadel AlShaibani is a Consultant Haematologist in Stem Cell Transplantation and Cellular Therapy, specialising in Lymphoma, Multiple Myeloma, and CAR-T cellular therapy — a leading haematology specialist in Riyadh, Saudi Arabia offering advanced blood cancer care to international patients. He serves as Head of a Virtual Care Department and as Assistant Professor and Co-Director of a Haematology Clerkship programme, combining clinical practice with academic medical education.
- Consultant Haematologist specialising in Lymphoma, Multiple Myeloma, and Stem Cell Transplantation
- Head of a Virtual Care Department — advancing remote oncology consultations for international patients
- Assistant Professor and Co-Director of a Haematology Clerkship — academic faculty role in medical education
- Published author on mantle cell lymphoma, DLBCL minimal residual disease, and relapsed/refractory Hodgkin lymphoma
- Internationally fellowship-trained in Stem Cell Transplantation and Cellular Therapy
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency
- Master of Business Administration (MBA) — Frankfurt School of Finance & Management, Germany
Fellowships & Special Training
- Fellowship in Adult Haematology
- Fellowship in Stem Cell Transplantation & Cellular Therapy — Weill Cornell Medicine, New York, USA
- Advanced training in Lymphoma and Multiple Myeloma
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Consultant
- American Society of Hematology (ASH) — Member
- European Society for Blood and Marrow Transplantation (EBMT) — Member
Areas of Expertise
Major Conditions Treated
- Hodgkin Lymphoma (Newly Diagnosed and Relapsed/Refractory)
- Non-Hodgkin Lymphoma (DLBCL, Follicular, Marginal Zone)
- Mantle Cell Lymphoma
- Multiple Myeloma
- T-Cell Acute Lymphoblastic Leukaemia (T-ALL)
- Plasma Cell Disorders
- AL Amyloidosis
- Waldenström Macroglobulinaemia
Sub-specialties
- Lymphoma & Myeloma Management: Evidence-based systemic therapy with proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and checkpoint inhibitors — a trusted lymphoma and myeloma specialist in Riyadh for international patients.
- Stem Cell Transplantation: Autologous and allogeneic haematopoietic stem cell transplantation for haematological malignancies, including haploidentical transplantation.
- CAR-T Cellular Therapy & Virtual Care: CD19-directed CAR-T cell therapy for relapsed/refractory B-cell malignancies; leads the Virtual Care Department providing remote haematology consultations for international patients.
Advanced Procedures & Treatments
- Autologous Stem Cell Transplantation (ASCT)
- Allogeneic Stem Cell Transplantation (Matched and Haploidentical)
- CD19 CAR-T Cell Therapy (Axi-cel, Tisagenlecleucel, Liso-cel)
- BCMA-directed Therapy for Multiple Myeloma
- Bispecific T-Cell Engagers (BiTEs)
- Acalabrutinib and BTK Inhibitor Therapy (Mantle Cell Lymphoma)
- Nivolumab / Checkpoint Inhibitor Therapy (Relapsed Hodgkin)
- Minimal Residual Disease Monitoring
Professional Experience
Current Affiliation
- Consultant Haematologist, Lymphoma / Myeloma Section — King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia (Present)
- Head, Virtual Care Department — KFSHRC, Riyadh (Present)
- Assistant Professor & Co-Director, Haematology Clerkship — Alfaisal University College of Medicine, Riyadh (Present)
Past Affiliations
- Fellow in Stem Cell Transplantation & Cellular Therapy — Weill Cornell Medicine, New York, USA
- Haematology Fellowship — King Faisal Specialist Hospital & Research Centre, Riyadh
Academic & Research Roles
- Co-Director, Haematology Clerkship — Alfaisal University College of Medicine
- Clinical Investigator — multiple international and regional haematology trials
Key Achievements
- Published author on DLBCL minimal residual disease
- Co-author on acalabrutinib in mantle cell lymphoma
- Contributor to publication on nivolumab in relapsed Hodgkin lymphoma
- Lead author on T-cell acute lymphoblastic leukaemia outcomes in adolescent and young adult patients
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Society for Blood and Marrow Transplantation (EBMT)
- Saudi Society of Haematology
- Saudi Commission for Health Specialties (SCFHS)
Research & Publications
Published Papers (Selected)
- Atout M, AlShaibani A, et al. Minimal Residual Disease in Diffuse Large B-Cell Lymphoma. 2025.
- Barrett A, AlShaibani A, et al. Acalabrutinib in Mantle Cell Lymphoma. eJHaem. 2024. PMC10887248.
- Farhan S, AlShaibani A, et al. Nivolumab in Relapsed/Refractory Hodgkin Lymphoma. Blood. 2022;140(Suppl 1):12048.
- AlShaibani A, et al. T-Cell Acute Lymphoblastic Leukaemia in Adolescents and Young Adults — Outcomes Analysis.
Ongoing Research & Clinical Interests
- Minimal residual disease in aggressive B-cell lymphomas
- CAR-T cell therapy outcomes in Middle East populations
- Virtual care and tele-haematology for international patients
- Haploidentical stem cell transplantation
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Haematology Consultation | ₹1,000 – ₹2,500 | $12 – $30 |
| Bone Marrow Biopsy & Aspirate | ₹8,000 – ₹25,000 | $100 – $300 |
| Chemotherapy (per cycle) | ₹40,000 – ₹2,00,000 | $480 – $2,400 |
| Autologous Stem Cell Transplant | ₹12,00,000 – ₹18,00,000 | $14,500 – $21,700 |
| Allogeneic Stem Cell Transplant | ₹18,00,000 – ₹30,00,000 | $21,700 – $36,100 |
| CAR-T Cell Therapy | ₹1,50,00,000 – ₹4,00,00,000 | $180,000 – $480,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. AlFadel AlShaibani use in Haematology — Lymphoma & Myeloma treatment?
Dr. AlFadel AlShaibani uses advanced haematology and cellular therapy technologies including CD19 CAR-T cell therapy (Axi-cel, Tisagenlecleucel), bispecific T-cell engagers, BCMA-targeted therapy for multiple myeloma, acalabrutinib and BTK inhibitors, checkpoint inhibitors (nivolumab, pembrolizumab), haploidentical stem cell transplantation, and minimal residual disease (MRD) monitoring. Virtual consultations and remote second opinions are also available to international patients through Cancer Rounds.
2. What conditions does Dr. AlFadel AlShaibani specialize in treating?
Dr. AlFadel AlShaibani specialises in Lymphoma and Multiple Myeloma, treating Hodgkin lymphoma, non-Hodgkin lymphoma (DLBCL, follicular, marginal zone), mantle cell lymphoma, multiple myeloma, plasma cell leukaemia, AL amyloidosis, Waldenström macroglobulinaemia, and T-cell acute lymphoblastic leukaemia. International patients seeking the best lymphoma and myeloma specialist in India or Saudi Arabia benefit from his expertise in CAR-T therapy and stem cell transplantation.
3. How do I book an appointment with Dr. AlFadel AlShaibani?
Appointments with Dr. AlFadel AlShaibani can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. AlFadel AlShaibani?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. AlFadel AlShaibani, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. AlFadel AlShaibani offer second opinions for Haematology — Lymphoma & Myeloma cases?
Yes. Second opinion consultations for Lymphoma and Myeloma cases can be arranged via Cancer Rounds, leveraging Dr. AlFadel AlShaibani's leadership of the Virtual Care Department to provide remote evaluations for international patients considering CAR-T therapy or stem cell transplantation.
